| Literature DB >> 36101457 |
Hugo-Henrique Silva1,2,3, Valéria Tavares1,4,5, Maria-Raquel G Silva6,7,8,9, Beatriz Vieira Neto4,5, Fátima Cerqueira4,6,10, Rui Medeiros4,5,6,11,12.
Abstract
Genetic factors are among the major contributors to athletic performance. Although more than 150 genetic variants have been correlated with elite athlete status, genetic foundations of competition-facilitating behavior influencing elite performances are still scarce. This is the first study designed to examine the distribution of genetic determinants in the athletic performance of elite rink-hockey players. A total of 116 of the world's top best rink-hockey players (28.2 ± 8.7 years old; more than 50% are cumulatively from the best four world teams and the best five Portuguese teams), who participated at the elite level in the National Rink-Hockey Championship in Portugal, were evaluated in anthropometric indicators/measurements, training conditions, sport experience and sport injuries history. Seven genetic polymorphisms were analyzed. Polymorphism genotyping was performed using the TaqMan® Allelic Discrimination Methodology. Rink-hockey players demonstrated significantly different characteristics according to sex, namely anthropometrics, training habits, sports injuries and genetic variants, such as Vitamin D Receptor (VDR) rs731236 (p < 0.05). The Fatty Acid Amide Hydrolase (FAAH) rs324420 A allele was significantly associated with improved athletic performance (AA/AC vs. CC, OR = 2.80; 95% Cl, 1.23-6.35; p = 0.014; p = 0.008 after Bootstrap) and confirmed as an independent predictor among elite rink-hockey players (adjusted OR = 2.88; 95% Cl, 1.06-7.80; p = 0.038). Our results open an interesting link from FAAH-related biology to athletic performance.Entities:
Keywords: elite athlete; gene; performance; polymorphism; rink-hockey; sport; success
Year: 2022 PMID: 36101457 PMCID: PMC9312224 DOI: 10.3390/biology11071076
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Elite rink-hockey players’ characteristics (n = 116, 18 females and 98 males).
| Characteristics | Female ( | Male ( | Total ( |
|
|---|---|---|---|---|
| Age (years) * | 25.3 ± 7.9 | 28.8 ± 8.7 | 28.2 ± 8.7 | 0.117 |
| Body mass (kg) * | 67.4 ± 8.7 | 82.8 ± 10.5 | 79.0 ± 12.0 |
|
| Height (m) * | 1.73 ± 0.1 | 1.85 ± 0.1 | 1.82 ± 0.1 |
|
| BMI (kg/m2) * | 22.7 ± 2.6 | 24.3 ± 2.1 | 24.0 ± 2.2 |
|
| WHR * | 0.82 ± 0.06 | 0.88 ± 0.11 | 0.87 ± 0.11 |
|
| Hand length (cm) * | 22.3 ± 2.6 | 23.5 ± 2.0 | 23.3 ± 2.1 |
|
| Training experience (years) * | 19.4 ± 8.6 | 24.0 ± 8.7 | 23.3 ± 8.8 |
|
| Training frequency * | ||||
| days/week | 4.6 ± 0.8 | 5.9 ± 0.8 | 5.7 ± 0.9 |
|
| hours/day | 2.4 ± 0.9 | 2.4 ± 0.9 | 2.4 ± 0.9 |
|
| hours/week | 11.4 ± 6.5 | 14.3 ± 6.2 | 13.8 ± 6.3 |
|
| Participations in regional and national teams * | 26.44 ± 13.16 | 42.38 ± 37.78 | 39.9 ± 35.5 | 0.080 |
| Sport injury | ||||
| No | 17 (94.4) | 51 (52.0) | 68 (58.6) |
|
| Yes | 1 (5.6) | 47 (48.0) | 48 (41.4) | |
| Nationality | ||||
| Portuguese | 18 (100) | 78 (79.6) | 96 (82.8) | 0.113 |
| Others | -- | 20 (20.4) | 20 (17.2) | |
| Ethnicity | ||||
| Caucasian | 17 (94.4) | 96 (98.0) | 113 (97.4) | 0.956 |
| Others | 1 (5.6) | 3 (3.0) | 3 (2.6) | |
| Profession | ||||
| Athletes | -- | 45 (45.9) | 45 (38.8) |
|
| Student | 10 (55.6) | 25 (25.5) | 35 (30.2) | |
| Teacher | 2 (11.1) | 11 (11.2) | 13 (11.2) | |
| Physical therapist | 2 (11.1) | -- | 2 (1.7) | |
| Sport coordinator | -- | 1 (1.0) | 1 (0.9) | |
| Coach | -- | 1 (1.0) | 1 (0.9) | |
| Podiatrist | 1 (5.6) | -- | 1 (0.9) | |
| Other | 3 (16.7) | 15 (15.3) | 18 (15.5) | |
* Data presented as mean ± standard deviation. BMI: body mass index, CI: confidence interval, OR: odds ratio, WHR: waist circumference/hip circumference ratio. Bold values represent significant results (p < 0.05).
Selected polymorphisms’ description and TaqMan® assays used.
| Genetic | Functional Consequence | Gene | Encode Protein and Its Functions | TaqMan® Assays ID |
|---|---|---|---|---|
|
| C___1897306_10 | |||
| rs324420 |
|
| Fatty Acid Amide Hydrolase | |
|
| ||||
| rs8192678 |
|
| PPARG Coactivator 1 Alpha | C___1643192_20 |
| rs2016520 |
|
| Peroxisome Proliferator Activated Receptor Delta | C___8851952_30 |
| rs1801282 |
|
| Peroxisome Proliferator Activated Receptor Gamma | C___1129864_10 |
| rs731236 |
|
| Vitamin D Receptor | C___2404008_10 |
|
| ||||
| rs1042713 |
|
| Adrenoceptor Beta 2 | C___2084764_20 |
|
| ||||
| rs1799983 |
|
| Nitric Oxide Synthase 3 | C___3219460_20 |
The functional consequence of each polymorphism was defined according to Ensembl database [25]. The functions of encoded proteins were described based on GeneCards database [26] and UniProt database [27].
Genotype frequencies of the selected genetic polymorphisms in elite rink-hockey players (n = 116, 18 females and 98 males).
| Genotype | Female | Male | Total |
|
|---|---|---|---|---|
|
| ||||
| AA | 1 (5.6) | 3 (3.1) | 4 (3.4) | 0.789 |
| AC | 6 (33.3) | 28 (28.6) | 34 (29.3) | |
| CC | 11 (61.1) | 67 (68.4) | 78 (67.2) | |
|
| ||||
| TT | 2 (11.1) | 17 (17.3) | 19 (16.4) | 0.705 |
| CT | 9 (50.0) | 51 (52.0) | 60 (51.7) | |
| CC | 7 (38.9) | 30 (30.6) | 37 (31.9) | |
|
| ||||
| CC | 0 (0.0) | 5 (5.1) | 5 (4.3) | 0.395 |
| CT | 7 (38.9) | 32 (32.7) | 39 (33.6) | |
| TT | 11 (61.1)) | 61 (62.2) | 72 (62.1) | |
|
| ||||
| GG | 0 (0.0) | 4 (4.1) | 4 (3.4) | 0.494 |
| CG | 3 (16.7) | 14 (14.3) | 17 (14.7) | |
| CC | 15 (83.3) | 80 (81.6) | 95 (81.9) | |
|
| ||||
| GG | 1 (5.6) | 17 (17.3) | 18 (15.5) |
|
| AG | 13 (72.2) | 36 (36.7) | 49 (42.2) | |
| AA | 4 (22.2) | 45(45.9) | 49 (42.2) | |
|
| ||||
| AA | 3 (16.7) | 15 (15.3) | 18 (15.5) | 0.989 |
| AG | 8 (44.4) | 44 (44.9) | 52 (44.8) | |
| GG | 7 (38.9) | 39 (39.8) | 46 (39.7) | |
|
| ||||
| TT | 0 (0.0) | 14 (14.3) | 14 (12.1) | 0.212 |
| GT | 11 (61.1) | 47 (48.0) | 58 (50.0) | |
| GG | 7 (38.9) | 37 (37.8) | 44 (37.9) | |
Bold values represent the significant results (p < 0.05).
Multivariate analysis using binomial regression on the athletic performance considering FAAH rs324420 and relevant factors.
|
| OR | 95% CI |
|
|---|---|---|---|
|
| 2.88 |
|
|
| ( | |||
|
| 9.74 | 3.09–30.74 | 0.065 |
| (≥26 yrs. vs. <26 yrs. 1) | |||
|
| 2.48 | 0.50–12.30 | 0.265 |
| ( | |||
|
| 0.58 | 0.19–1.80 | 0.349 |
| (≥25 kg/m2 vs. <25 kg/m2 1) | |||
|
| 0.83 | 0.30–2.28 | 0.721 |
| (≥0.85 vs. <0.85 1) | |||
| 0.35 | 0.12–1.02 | 0.054 | |
| (≥23 cm vs. <23 cm 1) | |||
|
| 3.71 |
|
|
| ( | |||
|
| 0.64 | 0.15–2.73 | 0.541 |
| (≥10 months vs. <10 months 1) |
1 Reference group. * Variable categories were defined based on median of variable values. BMI: body mass index, CI confidence interval, OR odds ratio, WHR: waist circumference/hip circumference ratio. Bold values represent the significant results (p < 0.05).
Figure 1Endocannabinoid system as regulator of stress response. Under normal circumstances (A), the endocannabinoid system suppresses the release of the neurotransmitter glutamate via AEA, modulating the synaptic function. However, acute stress (B) can trigger a mechanism mediated by CRH and its receptor CRHR1, which is known to increase FAAH activity in the basolateral amygdala. As a result, there is a decrease in AEA levels, which is no longer able to suppress glutamate release. Consequently, increased neural excitability in the basolateral amygdala promotes anxiety-like behavior (adapted by Lutz et al.) [41]. CB1R: cannabinoid type 1 receptor; Gq: family G protein; mGluR5: metabotropic glutamate receptor 5; AEA: N-arachidonoylethanolamine; 2-AG: 2-arachidonoyl glycerol; DAGLα: diacylglycerol lipase-α; PTP1B: protein tyrosine phosphatase 1B; FAAH: fatty acid amide hydrolase; NMDAR: NMDA receptor; LMO4: LIM domain only 4; CRH: corticotropin-releasing hormone; CRHR1: corticotropin-releasing hormone receptor 1.